Meta-analysis finds lower incidence of haematological toxicity versus similar drugs.
Background
- The immune checkpoint inhibitor nivolumab is approved in the US and Europe for at least 10 cancer types, including melanoma, non-small cell lung cancer, renal cell carcinoma, and gastric cancer.
- Nivolumab works by inhibiting the immunosuppressive molecule programmed cell...